Prediction of therapy‐related acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) after autologous bone marrow transplant (ABMT) for lymphoma
Therapy‐related acute myelogenous leukemia and myelodysplastic syndrome (t‐AML/MDS) are being reported with increasing frequency as a complication of ABMT for Hodgkin's disease and non‐Hodgkin's lymphoma. At present there is no method available to predict who is at risk or is destined to d...
Gespeichert in:
| Veröffentlicht in: | American journal of hematology 1997-09, Vol.56 (1), p.45-51 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 51 |
|---|---|
| container_issue | 1 |
| container_start_page | 45 |
| container_title | American journal of hematology |
| container_volume | 56 |
| creator | Legare, Robert D. Gribben, John G. Maragh, Marlon Hermanowski‐Vosatka, Anne Roach, Sheila Tantravahi, Ramana Nadler, Lee M. Gilliland, D. Gary |
| description | Therapy‐related acute myelogenous leukemia and myelodysplastic syndrome (t‐AML/MDS) are being reported with increasing frequency as a complication of ABMT for Hodgkin's disease and non‐Hodgkin's lymphoma. At present there is no method available to predict who is at risk or is destined to develop this nearly universally fatal disorder. We therefore investigated whether clonal growth of cells is predictive of the development of t‐AML/MDS. In a patient who developed secondary AML/MDS 18 months after ABMT, X‐linked clonality analysis at the human androgen receptor locus was performed on serial banked samples, and documented transition from polyclonal to clonal hematopoiesis. Clonal cells could be identified 6 months after transplant (1 year prior to the diagnosis of t‐AML/MDS), at a time when there was no morphologic or clinical evidence of disease. Clonality analysis can be predictive of the development of t‐AML/MDS after ABMT and may offer important insights into associated risk factors and strategies to minimize the risk of t‐AML/MDS. Am. J. Hematol. 56:45–51, 1997. © 1997 Wiley‐Liss, Inc. |
| doi_str_mv | 10.1002/(SICI)1096-8652(199709)56:1<45::AID-AJH10>3.0.CO;2-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79277033</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79277033</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3810-c6c119818ce12f8caed4190317db5c2993ef915bdbcc45cf84e4978f8fb1724c3</originalsourceid><addsrcrecordid>eNp9kc2O0zAUhSMEGjoDj4DkBULtIsWO82N3RkidDDBFrYo0ZW05zjUTSOJiJxplxyPwBrwbT4JDq25ArGz5nnvu8f2C4IrgOcE4ej29W-WrGcE8DVmaRFPCeYb5LEkX5CpOFovl6iZcfrgl-A2d43m-vYxC8iiYnBoeBxNMU-LvmD8Nzp37gjEhMcNnwRmPOGMpmwQ_P1ooK9VVpkVGo-4erNwPv77_sFDLDkokVd8BagaozWdoTe9QDf1XaCqJpsvNeoZkWx7K5eD2tXRdpZAb2tKaBtB0c3PnJboDi2TfGW8yWhSm9Z7SWvOAOivbsbHtvOH1ZjdD2lhUD83-3jTyWfBEy9rB8-N5EXx693aX34br7ftVvlyHijKCQ5UqQjgjTAGJNFMSyphwTElWFomKOKegOUmKslAqTpRmMcQ8Y5rpgmRRrOhF8Orgu7fmWw-uE03lFNQ-F_jEIuNRlmFKvXB3ECprnLOgxd5W_iuDIFiM3IQYuYkRgxgxiAM3kaSCiDgRwnMTf7gJKrDIt8JLvO2L4_y-aKA8mR5B-frLY106JWvtl6Yqd5JFDKeMp_S0noeqhuGvaP9P9q9ghwf6G59gwrw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79277033</pqid></control><display><type>article</type><title>Prediction of therapy‐related acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) after autologous bone marrow transplant (ABMT) for lymphoma</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Wiley Online Library Free Content</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Legare, Robert D. ; Gribben, John G. ; Maragh, Marlon ; Hermanowski‐Vosatka, Anne ; Roach, Sheila ; Tantravahi, Ramana ; Nadler, Lee M. ; Gilliland, D. Gary</creator><creatorcontrib>Legare, Robert D. ; Gribben, John G. ; Maragh, Marlon ; Hermanowski‐Vosatka, Anne ; Roach, Sheila ; Tantravahi, Ramana ; Nadler, Lee M. ; Gilliland, D. Gary</creatorcontrib><description>Therapy‐related acute myelogenous leukemia and myelodysplastic syndrome (t‐AML/MDS) are being reported with increasing frequency as a complication of ABMT for Hodgkin's disease and non‐Hodgkin's lymphoma. At present there is no method available to predict who is at risk or is destined to develop this nearly universally fatal disorder. We therefore investigated whether clonal growth of cells is predictive of the development of t‐AML/MDS. In a patient who developed secondary AML/MDS 18 months after ABMT, X‐linked clonality analysis at the human androgen receptor locus was performed on serial banked samples, and documented transition from polyclonal to clonal hematopoiesis. Clonal cells could be identified 6 months after transplant (1 year prior to the diagnosis of t‐AML/MDS), at a time when there was no morphologic or clinical evidence of disease. Clonality analysis can be predictive of the development of t‐AML/MDS after ABMT and may offer important insights into associated risk factors and strategies to minimize the risk of t‐AML/MDS. Am. J. Hematol. 56:45–51, 1997. © 1997 Wiley‐Liss, Inc.</description><identifier>ISSN: 0361-8609</identifier><identifier>EISSN: 1096-8652</identifier><identifier>DOI: 10.1002/(SICI)1096-8652(199709)56:1<45::AID-AJH10>3.0.CO;2-1</identifier><identifier>PMID: 9298868</identifier><identifier>CODEN: AJHEDD</identifier><language>eng</language><publisher>New York: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Alleles ; autologous bone marrow transplant ; Biological and medical sciences ; Bone Marrow Transplantation - adverse effects ; chemotherapy ; clonality ; Female ; Hematologic and hematopoietic diseases ; Hematopoiesis - genetics ; Humans ; leukemia ; Leukemia, Myeloid, Acute - diagnosis ; Leukemia, Myeloid, Acute - etiology ; Leukemia, Myeloid, Acute - genetics ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; lymphoma ; Lymphoma - therapy ; Medical sciences ; myelodysplasia ; Myelodysplastic Syndromes - diagnosis ; Myelodysplastic Syndromes - etiology ; Myelodysplastic Syndromes - genetics ; Polymerase Chain Reaction ; Predictive Value of Tests ; Receptors, Androgen - genetics ; secondary malignancy ; Transplantation, Autologous ; X Chromosome</subject><ispartof>American journal of hematology, 1997-09, Vol.56 (1), p.45-51</ispartof><rights>Copyright © 1997 Wiley‐Liss, Inc.</rights><rights>1997 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3810-c6c119818ce12f8caed4190317db5c2993ef915bdbcc45cf84e4978f8fb1724c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2F%28SICI%291096-8652%28199709%2956%3A1%3C45%3A%3AAID-AJH10%3E3.0.CO%3B2-1$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2F%28SICI%291096-8652%28199709%2956%3A1%3C45%3A%3AAID-AJH10%3E3.0.CO%3B2-1$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2806896$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9298868$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Legare, Robert D.</creatorcontrib><creatorcontrib>Gribben, John G.</creatorcontrib><creatorcontrib>Maragh, Marlon</creatorcontrib><creatorcontrib>Hermanowski‐Vosatka, Anne</creatorcontrib><creatorcontrib>Roach, Sheila</creatorcontrib><creatorcontrib>Tantravahi, Ramana</creatorcontrib><creatorcontrib>Nadler, Lee M.</creatorcontrib><creatorcontrib>Gilliland, D. Gary</creatorcontrib><title>Prediction of therapy‐related acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) after autologous bone marrow transplant (ABMT) for lymphoma</title><title>American journal of hematology</title><addtitle>Am J Hematol</addtitle><description>Therapy‐related acute myelogenous leukemia and myelodysplastic syndrome (t‐AML/MDS) are being reported with increasing frequency as a complication of ABMT for Hodgkin's disease and non‐Hodgkin's lymphoma. At present there is no method available to predict who is at risk or is destined to develop this nearly universally fatal disorder. We therefore investigated whether clonal growth of cells is predictive of the development of t‐AML/MDS. In a patient who developed secondary AML/MDS 18 months after ABMT, X‐linked clonality analysis at the human androgen receptor locus was performed on serial banked samples, and documented transition from polyclonal to clonal hematopoiesis. Clonal cells could be identified 6 months after transplant (1 year prior to the diagnosis of t‐AML/MDS), at a time when there was no morphologic or clinical evidence of disease. Clonality analysis can be predictive of the development of t‐AML/MDS after ABMT and may offer important insights into associated risk factors and strategies to minimize the risk of t‐AML/MDS. Am. J. Hematol. 56:45–51, 1997. © 1997 Wiley‐Liss, Inc.</description><subject>Alleles</subject><subject>autologous bone marrow transplant</subject><subject>Biological and medical sciences</subject><subject>Bone Marrow Transplantation - adverse effects</subject><subject>chemotherapy</subject><subject>clonality</subject><subject>Female</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Hematopoiesis - genetics</subject><subject>Humans</subject><subject>leukemia</subject><subject>Leukemia, Myeloid, Acute - diagnosis</subject><subject>Leukemia, Myeloid, Acute - etiology</subject><subject>Leukemia, Myeloid, Acute - genetics</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>lymphoma</subject><subject>Lymphoma - therapy</subject><subject>Medical sciences</subject><subject>myelodysplasia</subject><subject>Myelodysplastic Syndromes - diagnosis</subject><subject>Myelodysplastic Syndromes - etiology</subject><subject>Myelodysplastic Syndromes - genetics</subject><subject>Polymerase Chain Reaction</subject><subject>Predictive Value of Tests</subject><subject>Receptors, Androgen - genetics</subject><subject>secondary malignancy</subject><subject>Transplantation, Autologous</subject><subject>X Chromosome</subject><issn>0361-8609</issn><issn>1096-8652</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc2O0zAUhSMEGjoDj4DkBULtIsWO82N3RkidDDBFrYo0ZW05zjUTSOJiJxplxyPwBrwbT4JDq25ArGz5nnvu8f2C4IrgOcE4ej29W-WrGcE8DVmaRFPCeYb5LEkX5CpOFovl6iZcfrgl-A2d43m-vYxC8iiYnBoeBxNMU-LvmD8Nzp37gjEhMcNnwRmPOGMpmwQ_P1ooK9VVpkVGo-4erNwPv77_sFDLDkokVd8BagaozWdoTe9QDf1XaCqJpsvNeoZkWx7K5eD2tXRdpZAb2tKaBtB0c3PnJboDi2TfGW8yWhSm9Z7SWvOAOivbsbHtvOH1ZjdD2lhUD83-3jTyWfBEy9rB8-N5EXx693aX34br7ftVvlyHijKCQ5UqQjgjTAGJNFMSyphwTElWFomKOKegOUmKslAqTpRmMcQ8Y5rpgmRRrOhF8Orgu7fmWw-uE03lFNQ-F_jEIuNRlmFKvXB3ECprnLOgxd5W_iuDIFiM3IQYuYkRgxgxiAM3kaSCiDgRwnMTf7gJKrDIt8JLvO2L4_y-aKA8mR5B-frLY106JWvtl6Yqd5JFDKeMp_S0noeqhuGvaP9P9q9ghwf6G59gwrw</recordid><startdate>199709</startdate><enddate>199709</enddate><creator>Legare, Robert D.</creator><creator>Gribben, John G.</creator><creator>Maragh, Marlon</creator><creator>Hermanowski‐Vosatka, Anne</creator><creator>Roach, Sheila</creator><creator>Tantravahi, Ramana</creator><creator>Nadler, Lee M.</creator><creator>Gilliland, D. Gary</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199709</creationdate><title>Prediction of therapy‐related acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) after autologous bone marrow transplant (ABMT) for lymphoma</title><author>Legare, Robert D. ; Gribben, John G. ; Maragh, Marlon ; Hermanowski‐Vosatka, Anne ; Roach, Sheila ; Tantravahi, Ramana ; Nadler, Lee M. ; Gilliland, D. Gary</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3810-c6c119818ce12f8caed4190317db5c2993ef915bdbcc45cf84e4978f8fb1724c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Alleles</topic><topic>autologous bone marrow transplant</topic><topic>Biological and medical sciences</topic><topic>Bone Marrow Transplantation - adverse effects</topic><topic>chemotherapy</topic><topic>clonality</topic><topic>Female</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Hematopoiesis - genetics</topic><topic>Humans</topic><topic>leukemia</topic><topic>Leukemia, Myeloid, Acute - diagnosis</topic><topic>Leukemia, Myeloid, Acute - etiology</topic><topic>Leukemia, Myeloid, Acute - genetics</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>lymphoma</topic><topic>Lymphoma - therapy</topic><topic>Medical sciences</topic><topic>myelodysplasia</topic><topic>Myelodysplastic Syndromes - diagnosis</topic><topic>Myelodysplastic Syndromes - etiology</topic><topic>Myelodysplastic Syndromes - genetics</topic><topic>Polymerase Chain Reaction</topic><topic>Predictive Value of Tests</topic><topic>Receptors, Androgen - genetics</topic><topic>secondary malignancy</topic><topic>Transplantation, Autologous</topic><topic>X Chromosome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Legare, Robert D.</creatorcontrib><creatorcontrib>Gribben, John G.</creatorcontrib><creatorcontrib>Maragh, Marlon</creatorcontrib><creatorcontrib>Hermanowski‐Vosatka, Anne</creatorcontrib><creatorcontrib>Roach, Sheila</creatorcontrib><creatorcontrib>Tantravahi, Ramana</creatorcontrib><creatorcontrib>Nadler, Lee M.</creatorcontrib><creatorcontrib>Gilliland, D. Gary</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Legare, Robert D.</au><au>Gribben, John G.</au><au>Maragh, Marlon</au><au>Hermanowski‐Vosatka, Anne</au><au>Roach, Sheila</au><au>Tantravahi, Ramana</au><au>Nadler, Lee M.</au><au>Gilliland, D. Gary</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prediction of therapy‐related acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) after autologous bone marrow transplant (ABMT) for lymphoma</atitle><jtitle>American journal of hematology</jtitle><addtitle>Am J Hematol</addtitle><date>1997-09</date><risdate>1997</risdate><volume>56</volume><issue>1</issue><spage>45</spage><epage>51</epage><pages>45-51</pages><issn>0361-8609</issn><eissn>1096-8652</eissn><coden>AJHEDD</coden><abstract>Therapy‐related acute myelogenous leukemia and myelodysplastic syndrome (t‐AML/MDS) are being reported with increasing frequency as a complication of ABMT for Hodgkin's disease and non‐Hodgkin's lymphoma. At present there is no method available to predict who is at risk or is destined to develop this nearly universally fatal disorder. We therefore investigated whether clonal growth of cells is predictive of the development of t‐AML/MDS. In a patient who developed secondary AML/MDS 18 months after ABMT, X‐linked clonality analysis at the human androgen receptor locus was performed on serial banked samples, and documented transition from polyclonal to clonal hematopoiesis. Clonal cells could be identified 6 months after transplant (1 year prior to the diagnosis of t‐AML/MDS), at a time when there was no morphologic or clinical evidence of disease. Clonality analysis can be predictive of the development of t‐AML/MDS after ABMT and may offer important insights into associated risk factors and strategies to minimize the risk of t‐AML/MDS. Am. J. Hematol. 56:45–51, 1997. © 1997 Wiley‐Liss, Inc.</abstract><cop>New York</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>9298868</pmid><doi>10.1002/(SICI)1096-8652(199709)56:1<45::AID-AJH10>3.0.CO;2-1</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0361-8609 |
| ispartof | American journal of hematology, 1997-09, Vol.56 (1), p.45-51 |
| issn | 0361-8609 1096-8652 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_79277033 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Wiley Online Library Free Content; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Alleles autologous bone marrow transplant Biological and medical sciences Bone Marrow Transplantation - adverse effects chemotherapy clonality Female Hematologic and hematopoietic diseases Hematopoiesis - genetics Humans leukemia Leukemia, Myeloid, Acute - diagnosis Leukemia, Myeloid, Acute - etiology Leukemia, Myeloid, Acute - genetics Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis lymphoma Lymphoma - therapy Medical sciences myelodysplasia Myelodysplastic Syndromes - diagnosis Myelodysplastic Syndromes - etiology Myelodysplastic Syndromes - genetics Polymerase Chain Reaction Predictive Value of Tests Receptors, Androgen - genetics secondary malignancy Transplantation, Autologous X Chromosome |
| title | Prediction of therapy‐related acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) after autologous bone marrow transplant (ABMT) for lymphoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T19%3A43%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prediction%20of%20therapy%E2%80%90related%20acute%20myelogenous%20leukemia%20(AML)%20and%20myelodysplastic%20syndrome%20(MDS)%20after%20autologous%20bone%20marrow%20transplant%20(ABMT)%20for%20lymphoma&rft.jtitle=American%20journal%20of%20hematology&rft.au=Legare,%20Robert%20D.&rft.date=1997-09&rft.volume=56&rft.issue=1&rft.spage=45&rft.epage=51&rft.pages=45-51&rft.issn=0361-8609&rft.eissn=1096-8652&rft.coden=AJHEDD&rft_id=info:doi/10.1002/(SICI)1096-8652(199709)56:1%3C45::AID-AJH10%3E3.0.CO;2-1&rft_dat=%3Cproquest_cross%3E79277033%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79277033&rft_id=info:pmid/9298868&rfr_iscdi=true |